Navarixin 是一种可口服的CXCR1和CXCR2变构拮抗剂，对猕猴CXCR1的Kd值为 41 nM，对大小鼠和猕猴CXCR2的Kd值分别为 0.20、0.20 和 0.08 nM。

Navarixin(SCH527123) is a novel, selective CXC chemokine receptor 2(CXCR2) antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia.

Navarixin is a potent, allosteric antagonist of both CXCR1 and CXCR2, with Kd values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly[1].

473727-83-2

C21H23N3O5

397.431

MK-7123;SCH 527123

DMSO:50 mg/mL (125.81 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years